Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib and Ziftomenib in NPM1/IDH1 Co-Mutated AML
NCT07411586Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib and olutasidenib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events, Recommended Phase 2 Dose and 1 more. Started May 2026; status: active, not recruiting.
02
Drugs
ziftomenibolutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07411586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411586.